Development of new antivirals for herpesviruses

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 6, 2003, Pages 299-308

  Eizuru, Yoshito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

HCMV; Herpes simplex virus; HHV; HSV; Human cytomegalovirus; Human herspesvirus; Nucleoside analogue

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 175 X; 4 OXODIHYDROQUINOLINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; BAY 571293; BENZIMIDAVIR; BILS 179BS; CIDOFOVIR; COMP 1; DNA POLYMERASE; DNA PRIMASE; ENZYME INHIBITOR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GW 275175X; HELICASE; K 252A; K 252C; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PENCICLOVIR; PNU 182171; PNU 183792; PNU 26370; PROTEIN KINASE; PYROPHOSPHORIC ACID DERIVATIVE; T 0902611; THYMIDINE KINASE; TOMEGLOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; VIRUS ENZYME; VIRUS PROTEIN; WAY 150138;

CELL CULTURE; CHEMOTHERAPY; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DNA SYNTHESIS INHIBITION; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HERPES VIRUS; HERPES VIRUS INFECTION; HOST; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE DISORDER; VIRUS CAPSID; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0842349132     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400602     Document Type: Review

References (61)

1. Akantitapichat P & Bastow KF (2000) The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Research 53:113-126.
2. Betz UA, Fischer R, Kleymann G, Hendrix M & Rubsamen-Waigmann H (2002) Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrobial Agents & Chemotherapy 46:1766-1772.
3. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith IA, Davis MG, Talarico CL, Townsend LB & Koszalka GW (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrobial Agents & Chemotherapy 46:2356-2372.
4. Black LW & Pellet PE (1999) Human herpesvirus 7. Review of Medical Virology 9:245-262.
5. Bonger E, Radsak K & Stinski MF (1998) The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. Journal of Virology 72:2257-2264.
6. Brideau RJ, Knechtel ML, Huang A, Vaillancourt VA, Vera EE, Oien NL, Hopkins TA, Wieber JL, Wilkinson KF, Rush BD, Schwende FJ & Wahen MW(2002) Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Research 54:19-28.
7. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, Graeper S, Klenk HD, Ruebsamen-Waigmann H & Hallenberger S (2001) A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. Journal of Virology 75:9077-9086.
8. Chee, MS, Bankeir AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnel T, Hutchinson CAI, Kouzaride T, Martignetti JA, Preddie E, Satchwell SP, Tomlinson P, Weston KM & Barrel BG (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Current Topics in Microbiology & Immunology 154:125-170.
9. Cihlar T & Chen MS (1996) Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Molecular Pharmacology 50:1502-1510.
10. Coen DM & Schaffer PA (2003) Antiherpesvirus drugs: a promising spectrum of new drugs and drug target. Nature Reviews Drug Discovery 2:278-288.
11. Crumpacker CS (1992) Mechanism of action of foscarnet against viral polymerase. American Journal of Medicine 92:3S-7S.
12. Crumpacker CS & Schaffer PA (2002) New anti-HSV therapeutics target the helicase-primase complex. Nature Medicine 8:327-328.
13. Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, Kiber P, Liuzzi M & Cordingley MG (2002) Herpes simplex virus helicase-primase inhibitors are active in animal models of human diseases. Nature Medicine 8:386-391.
14. Crute JJ & Lehman IR (1991) Herpes simplex virus helicase-primase. Physical and catalytic properties. Journal of Biological Chemistry 266:4484-4488.
15. De Clercq E & Walker RT (1984) Synthesis and antiviral properties of 5-vinyl-pyrimidine nucleoside analogs. Pharmacology & Therapy 26:1-44.
16. Elion GB (1983) The biochemistry and mechanism of action of acyclovir. Journal of Antimicrobial Chemotherapy 12 (Suppl. B):9-17.
17. Ensoli B, Sturzl M & Monini P (2001) Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Advance in Cancer Review 81:161-200.
18. Evers DL, Komazin G, Shin D, Hwang DD, Townsend LB & Drach JC (2002) Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Research 56:61-72.
19. Frenkel N & Wyatt LS (1992) HHV-6 and HHV-7 as exogeneous agents in human lymphocytes. Developmental Biology Standards 76:259-265.
20. Giesen K, Radsak K & Bogber E (2000) Targeting of the gene product encoded by ORF UL56 of human cytomegalovirus into viral replication centers. FEBS Letter 471:215-218.
21. Good SS, Owens BS, Townsend LB & Grach JC (1994) The disposition in rats and monkey of 2-bromo-5,6-dichloro-l-(β-D-ribofuranosyl) -benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antiviral Research 23:Suppl. I, 103.
22. Griffiths PD (1996) Herpesviruses and AIDS. Scandinanvian Journal of Infectious Diseases 100:3-7.
23. Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V, Baumeister J, Weber O, Henninger K, Keldenich J, Jensen A, Kolb J, Bach U, Popp A, Maben J, Frappa L, Haebich D, Lockhoff O & Rubsamen-Waigmann H (2002) New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine 8:392-398.
24. Knechtel ML, Huang A, Vaillancourt VA & Brideau RJ (2002) Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline. Journal of Medical Virology 68:234-236.
25. Krosky PM, Baek M & Coen DM (2003) Cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Journal of Virology 77:905-914.
26. Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB & Drach JC (1998) Resistance of human cytomegalovirus to bezimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Journal of Virology 72:4721-4728.
27. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowdden W, Talarico CL, Shaw S, Jacobson MA & Drew WL (2002) Phase I dose escalation trial evaluating the pahermacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrobial Agents & Chemotherapy 46:2969-2976.
28. Leeds JM, Henry SP, Yruong L, Zutshi A, Levin AA & Kornbrust D (1997) Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metabolism & Disposition: the Biological Fate of Chemicals 25:921-926
29. Litter E, Stuart AD & Chee MS (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
30. McGuigan C, Barucki H, Blewett S, Carangio A, Erichsen JT, Andrei G, Snocck R, De Clercq E & Balzarini J (2000) Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. Journal of Medical Chemistry 43:4993-4997.
31. McSharry JJ, McDonough A, Olson B, Tararico C, Davis M & Biron KK (2001) Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clinical Diagnosis & Laboratory Immunology 8:1279-1281.
32. Newcomb WW & Brown JC (1994) Induced extrusion of DNA from the capsid of herpes simplex virus type 1. Journal of Virology 68:433-440.
33. Newcomb WW, Juhas RM, Thomsen DR, Homa FL, Burch AD, Weller SK & Brown JC (2001a) The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. Journal of Virology 75:10923-10932.
34. Newcomb WW, Homa FL, Thomsen DR & Brown JC (2001b) In vitro assembly of the herpes simplex virus procapsid: formation of small procapsids at reduced scaffolding protein concentration. Journal of Structual Biology 133:23-31.
35. Newcomb WW & Brown JC (2002) Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsid depleted of the portal and terminase proteins involved in DNA encapsidation. Journal of Virology 76:10084-10088.
36. Neyts J & De Clercq E (1994) Mechanism of action of acyclic nucleoside phosphonate against herpes virus replication. Biochemical Pharmacology 47:39-41.
37. Perry CM & Balfour JA (1999) Fomivirsen. Drugs 57:375-380.
38. Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, Haerter M, Buerger I, Trappe J, Herrington JA, Haebich D & Ruebsamen-Waigmann H (2001) Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. Journal of Antimicrobial Chemotherapy 48:757-767.
39. Schang LM, Bantly A, Knockaert M, Shaheen FF, Meijer L, Malim MH, Gray NS & Schaffer PA (2002) Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. Journal of Virology 76:7874-7882.
40. Scheffczik H, Savva CG, Holzenburg A, Kolesnikova L & Bogner E (2002) The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Research 30:1695-1703.
41. Scholz B, Rechter S, Drach JC, Townsend LB & Bogner E (2003) Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Research 31:1426-1433.
42. Severini A, Scraba DG & Tyrrell DL (1996) Branched structures in the intracellular DNA of herpes simplex virus type 1. Journal of Virology 70:3169-3175.
43. Sissons JG & Carmichael AJ (2002) Clinical aspects and management of cytomegalovirus infection. Journal of Infection 44:78-83.
44. Sjovall J, Karlsson A, Ogenstad S, Sandstrom E & Saarimaki M (1988) Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clinical Pharmacology & Therapy 44:65-73.
45. Tomsen DR, Oien NL, Hopkins TA, Knechtel ML, Brideau RJ, Wathen MW & Homa FL (2003) Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. Journal of Virology 77:1868-1876.
46. Townsend LB, Devivar RV, Turk SR, Nassiri MR & Drach JC (1995) Design, synthesis, and antiviral activity of certain 2,5,6-tri-halo-1-(beta-D-ribofuranosyl)benzimidazoles. Journal of Medical Chemistry 38:4098-4105.
47. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB & Biron KK (1998) Inhibition of human cytomegalovirus DNA maturation by a benzimidazole reibonucleoside is mediated through the UL89 gene product. Journal of Virology 72:717-725.
48. van Zeijl M, Fairhurst J, Jones TR, Vernon SK, Morin J, LaRocque J, Feld B, O'Hara B, Bloom JD & Johann SV (2000) Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. Journal of Virology 74:9054-9061.
49. Visalli RJ, Fairhurst J, Srinivas S, Hu W, Feld B, DiGrandi M, Curran K, Ross A, Bloom JD, van Zeijil M, Jones TR, O'Connell J & Cohn JI (2003) Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. Journal of Virology 77:2349-2358.
50. Visalli RJ & van Zeijl M (2003) DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Research 59:73-87.
51. Wathen MW (2002) Non-nucleoside inhibitors of herpesviruses. Review of Medical Virology 12:167-178.
52. Weber O, Bender W, Eckenberg P, Goldmann S, Haerter M, Hallenberger S, Henninger K, Reefschlager J, Trappe J, Witt-Laido A & Ruebsamen-Waigmann H (2001) Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleoside compound in vivo. Antiviral Research 49:179-189.
53. Whitley RJ & Roizman B (2001) Herpes simplex virus infections. Lancet 357:1513-1518.
54. Williams SW, Hartline CB, Kushner NL, Harden EA, Bidanst DJ, Drach JC, Townsend LB, Underwood MR, Biron KK & Kern ER (2003) In vitro activitites of benzimidazole D- and L-robonucleosides against herpesviruses. Antimicrobial Agents & Chemotherapy 47:2186-2192.
55. Wolf DG, Courcelle CT, Prichard MN & Mocarski ES (2001) Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proceedings of the National Academy of Science, USA 98:1895-1900.
56. Wutzler P, De Clercq E, Wutke K & Farber L (1995) Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. Journal of Medical Virology 46:252-257.
57. Zhang X, Efstathiou S & Simmons A (1994) Identification of novel herpes simplex virus replicative intermediates by field inversion gel electrophoresis: implications for viral DNA amplification strategies. Virology 202:32-44.
58. Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T (2000) Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Research 48:49-60.
59. Zhu H, Cong JP, Yu D, Breshnahan WA & Shenk TE (2002) Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proceedings of National Academy of Science, USA 99:3932-3937.
60. Zhu LA & Weller SK (1992) The UL5 gene of herpes simplex virus type 1: Isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex. Journal of Virology 66:1458-1468.
61. Zhuravskaya T, Maciejewski JP, Netski DM, Bruening E, Mackintosh FR & St Jeor S (1997) Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood 90:2482-2491.